The tepid reception to Venture Global's ambitious valuation target shows companies need to set realistic expectations when ...

Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s ...

After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

Reports suggest that markets are projected to bounce back, making 2025 one of the strongest years in recent memory for ...

The China-based cancer drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

In a moment of buzzy optimism known as “Web 2.0,” Julia Hartz started Eventbrite with Kevin Hartz, then her fiancé and soon her husband, and Renaud Visage. That was 2006. Fast forward nearly two ...

A global biopharma with a U.S. headquarters in Montgomery County is gearing up to go public on a U.S. exchange.

The latest spin-off proposal comes from Euroseas and offshoot Euroholdings. And as Lightbourn notes, the Aristides Pittas-led ...

The diabetes startup is prescribing GLP-1 drugs for weight loss to help employers manage costs. Its CEO says it's nearing ...

This is the first IPO from the dental care industry. The city-based company has marginally lowered the size of the fresh issuance from Rs 150 crore to Rs 138 crore but marginally expanded the ...

Raymond James analyst Michael Glen downgraded Aritzia (ATZAF) to Market Perform from Outperform with a price target of C$58, up from C$52.50, ahead of the Q3 earnings report. The downgrade is ...